Opioid dependency. Mental and behavioral disorders due to use of opioids
Conditions
Interventions
Intervention 1: Intervention group 1: 8 mg buprenorphine is given as a sublingual single dose to patients and evaluated for at least 5 days. Intervention 2: Intervention group 2: 2 mg buprenorphine is
Treatment - Drugs
Intervention group 1: 8 mg buprenorphine is given as a sublingual single dose to patients and evaluated for at least 5 days.
Intervention group 2: 2 mg buprenorphine is given as a sublingual single dose to patients and evaluated for at least 5 days.
Control group: Placebo is given as a sublingual single dose to patients and evaluated for at least 5 days.
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
16 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria:age between 16 to 60 y/o; informed consent;Opioid dependence Exclusion criteria:Patients unwilling to participate at beginning or during the study; use of other substances except Opioid as of the main substance
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Withdrawal symptoms in opioid dependents. Timepoint: before the first dose and first day to 4 days. Method of measurement: Interview and questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Anxiety, depression in opioid dependents. Timepoint: Before the first dose and first day to 4 days. Method of measurement: Interview and questionnaires. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactJamshid Ahmadi M.D.
Shiraz University of Medical Sciences
Outcome results
None listed